Chris Gibson: Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead.

Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Recursion Pharmaceuticals rises 10.7% Recursion Pharmaceuticals rises 16.8% Unusually active option classes on open July 21st Recursion Pharmaceuticals call volume above normal and directionally ...